AbbVie Inc. (ABBV) FY2024 Q3 Statement of Cash Flows

Statement of Cash Flows

2024-07-01 to 2024-09-30

Swipe to see the full flow
AbbVie Inc. cash flow reconciliation, Jul 1, 2024 through Sep 30, 2024One connected Sankey reconciles operating, investing and financing net cash flows through a shared cash pool, from beginning cash to ending cash. Ribbons flow left to right on one dollar scale. Activity totals are dark gray; beginning and ending cash are blue. Cash basis for beginning and ending balances and net cash change: Cash, cash equivalents, and restricted cash. Intermediate calculation bars are lighter gray. Net income is green for profit and red for loss. Identified asset purchases, sales and maturities are blue in either cash direction. Purple identifies capital transactions such as borrowing, repayments, share issuance and dividends. Free cash flow is a separate comparison, not an added cash flow. Read chart description and values below for full signed amounts, including zero items.Net earnings → Net cash from operating activities: $1,564,000,000.00Amortization of intangible assets → Operating adjustments reconciliation: $1,888,000,000.00Change in fair value of contingent consideration liabilities → Operating adjustments reconciliation: $1,356,000,000.00Accounts receivable → Operating adjustments reconciliation: $344,000,000.00Non-cash litigation reserve adjustments, net of cash payments → Operating adjustments reconciliation: $314,000,000.00Accounts payable and other liabilities → Operating adjustments reconciliation: $267,000,000.00Depreciation → Operating adjustments reconciliation: $191,000,000.00Stock-based compensation → Operating adjustments reconciliation: $181,000,000.00Prepaid expenses and other assets → Operating adjustments reconciliation: $152,000,000.00Acquired IPR&D and milestones → Operating adjustments reconciliation: $82,000,000.00Income tax assets and liabilities, net → Operating adjustments reconciliation: $51,000,000.00Operating adjustments reconciliation → Net cash from operating activities: $3,883,000,000.00Operating adjustments reconciliation → Payment for Contingent Consideration Liability, Operating Activities: $580,000,000.00Operating adjustments reconciliation → Deferred income taxes: $277,000,000.00Operating adjustments reconciliation → Inventories: $64,000,000.00Operating adjustments reconciliation → Other, net: $22,000,000.00Sales and maturities of investment securities → investing reconciliation: $507,000,000.00Other, net → investing reconciliation: $3,000,000.00investing reconciliation → Payments to Acquire Businesses, Net of Cash Acquired: $8,294,000,000.00investing reconciliation → Acquisitions of property and equipment: $249,000,000.00investing reconciliation → Other acquisitions and investments: $199,000,000.00investing reconciliation → Purchases of investment securities: $24,000,000.00Net cash used in financing activities → financing reconciliation: $3,072,000,000.00Proceeds from the exercise of stock options → financing reconciliation: $67,000,000.00Other, net → financing reconciliation: $32,000,000.00financing reconciliation → Dividends paid: $2,751,000,000.00financing reconciliation → Repayments of long-term debt and finance lease obligations: $403,000,000.00financing reconciliation → Purchases of treasury stock: $17,000,000.00Net cash used in investing activities → investing reconciliation: $8,256,000,000.00Exchange-rate effect → Cash sources and uses: $8,000,000.00Beginning cash: Cash, cash equivalents, and restricted cash → Cash sources and uses: $13,130,000,000.00Net cash from operating activities → Cash sources and uses: $5,447,000,000.00Cash sources and uses → Ending cash: Cash, cash equivalents, and restricted cash: $7,257,000,000.00Cash sources and uses → Net cash used in investing activities: $8,256,000,000.00Cash sources and uses → Net cash used in financing activities: $3,072,000,000.00Change in fair value of contingent consideration liabilities: $1,356,000,000.00Contingent consideration change+$1.36 BAmortization of intangible assets: $1,888,000,000.00Intangible amortization+$1.89 BAcquired IPR&D and milestones: $82,000,000.00Acquired IPR&D written off+$82.00 MAccounts payable and other liabilities: $267,000,000.00Payables & accrued liabilities+$267.00 MPrepaid expenses and other assets: $152,000,000.00Prepaid & other assets+$152.00 MImpairment of intangible assets: $0.00Other, net: -$22,000,000.00Other non-cash items−$22.00 MStock-based compensation: $181,000,000.00Stock-based compensation+$181.00 MInventories: -$64,000,000.00Inventories−$64.00 MIncome tax assets and liabilities, net: $51,000,000.00Income taxes, net+$51.00 MNet earnings: $1,564,000,000.00Net earnings+$1.56 BDepreciation: $191,000,000.00Depreciation expense+$191.00 MDeferred income taxes: -$277,000,000.00Deferred income taxes−$277.00 MAccounts receivable: $344,000,000.00Accounts receivable+$344.00 MPayment for Contingent Consideration Liability, Operating Activities: -$580,000,000.00Contingent consideration paid−$580.00 MNon-cash litigation reserve adjustments, net of cash payments: $314,000,000.00Non-cash litigation, net+$314.00 MNet cash from operating activities: $5,447,000,000.00Operating cash+$5.45 BOperating adjustments reconciliation: $4,826,000,000.00Payments of Debt Issuance Costs: $0.00Dividends paid: -$2,751,000,000.00Dividends paid−$2.75 BPurchases of treasury stock: -$17,000,000.00Common stock repurchases−$17.00 MRepayments of other short-term borrowings: $0.00Proceeds from the exercise of stock options: $67,000,000.00Stock option exercises+$67.00 MPayments of contingent consideration liabilities: $0.00Other, net: $32,000,000.00Other financing, net+$32.00 MProceeds from Short-Term Debt: $0.00Repayments of long-term debt and finance lease obligations: -$403,000,000.00Debt & capital securities repaid−$403.00 MProceeds from issuance of long-term debt: $0.00Net cash used in financing activities: -$3,072,000,000.00. Cash required to fund net payments.Financing cash−$3.07 Bfinancing reconciliation: $3,171,000,000.00Acquisitions of property and equipment: -$249,000,000.00PP&E purchases−$249.00 MPurchases of investment securities: -$24,000,000.00Marketable securities purchases−$24.00 MOther acquisitions and investments: -$199,000,000.00Other investment purchases−$199.00 MOther, net: $3,000,000.00Other investing, net+$3.00 MSales and maturities of investment securities: $507,000,000.00Investment sales & maturities+$507.00 MPayments to Acquire Businesses, Net of Cash Acquired: -$8,294,000,000.00Acquisitions, net of cash−$8.29 BNet cash used in investing activities: -$8,256,000,000.00. Cash required to fund net payments.Investing cash−$8.26 Binvesting reconciliation: $8,766,000,000.00Cash sources and uses: $18,585,000,000.00Beginning cash: Cash, cash equivalents, and restricted cash: $13,130,000,000.00Beginning cash$13.13 BEnding cash: Cash, cash equivalents, and restricted cash: $7,257,000,000.00Ending cash$7.26 BExchange-rate effect: $8,000,000.00FX effect+$8.00 MCASH RECONCILIATIONOperatingflowsInvestingflowsFinancingflowsFree cash flow$5.20 BOperating cash − cash spent on PP&ECash flow / Net income3.48×Operating cash flow ÷ net incomeNet cash change−$5.87 BEnding cash − beginning cash
Chart details

AbbVie Inc. cash flow reconciliation, Jul 1, 2024 through Sep 30, 2024

Cash flows for Jul 1, 2024 through Sep 30, 2024. Cash basis: Cash, cash equivalents, and restricted cash. Beginning cash: Jun 30, 2024. Ending cash: Sep 30, 2024. Beginning and ending cash are dated balances. Positive cash flows add cash; negative cash flows reduce it.

Beginning cash on Jun 30, 2024
13,130,000,000 US dollars. Beginning cash: Cash, cash equivalents, and restricted cash
Operating activities
5,447,000,000 US dollars. Net cash provided.
Change in fair value of contingent consideration liabilities
1,356,000,000 US dollars
Amortization of intangible assets
1,888,000,000 US dollars
Acquired IPR&D and milestones
82,000,000 US dollars
Accounts payable and other liabilities
267,000,000 US dollars
Prepaid expenses and other assets
152,000,000 US dollars
Impairment of intangible assets
0 US dollars
Other, net
negative 22,000,000 US dollars
Stock-based compensation
181,000,000 US dollars
Inventories
negative 64,000,000 US dollars
Income tax assets and liabilities, net
51,000,000 US dollars
Net earnings
1,564,000,000 US dollars
Depreciation
191,000,000 US dollars
Deferred income taxes
negative 277,000,000 US dollars
Accounts receivable
344,000,000 US dollars
Payment for Contingent Consideration Liability, Operating Activities
negative 580,000,000 US dollars
Non-cash litigation reserve adjustments, net of cash payments
314,000,000 US dollars
Investing activities
negative 8,256,000,000 US dollars. Net cash used.
Acquisitions of property and equipment
negative 249,000,000 US dollars
Purchases of investment securities
negative 24,000,000 US dollars
Other acquisitions and investments
negative 199,000,000 US dollars
Other, net
3,000,000 US dollars
Sales and maturities of investment securities
507,000,000 US dollars
Payments to Acquire Businesses, Net of Cash Acquired
negative 8,294,000,000 US dollars
Financing activities
negative 3,072,000,000 US dollars. Net cash used.
Payments of Debt Issuance Costs
0 US dollars
Dividends paid
negative 2,751,000,000 US dollars
Purchases of treasury stock
negative 17,000,000 US dollars
Repayments of other short-term borrowings
0 US dollars
Proceeds from the exercise of stock options
67,000,000 US dollars
Payments of contingent consideration liabilities
0 US dollars
Other, net
32,000,000 US dollars
Proceeds from Short-Term Debt
0 US dollars
Repayments of long-term debt and finance lease obligations
negative 403,000,000 US dollars
Proceeds from issuance of long-term debt
0 US dollars
Operating adjustment reconciliation
4,826,000,000 US dollars. Intermediate calculation joining the operating reconciliation branches. Its gross amount includes any portion of net income routed through this junction. It is not an additional cash source or use.
financing gross reconciliation
3,171,000,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
investing gross reconciliation
8,766,000,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
Exchange-rate effect
8,000,000 US dollars
Ending cash on Sep 30, 2024
7,257,000,000 US dollars. Ending cash: Cash, cash equivalents, and restricted cash
Cash sources and uses
18,585,000,000 US dollars. Opening cash plus net sources, equal to net uses plus ending cash.
Net cash change
negative 5,873,000,000 US dollars. Ending cash minus beginning cash.
Cash flow / Net income
3.48×. Operating cash flow divided by reconciliation net income for the same period. Black from 0.90× through 1.10×; green above 1.10×; red below 0.90×. Color uses the unrounded ratio.
Operating cash flow
5,447,000,000 US dollars. Operating cash flow used in the free cash flow calculation.
Cash purchases of property, plant and equipment
249,000,000 US dollars. These cash purchases are already included in investing activities above.
Free cash flow
5,198,000,000 US dollars. A supplemental measure; finance-lease payments are excluded from this definition.

Chart connections

  • Beginning cash plus operating, investing and financing cash flows plus the exchange-rate effect equals ending cash. Negative amounts reduce cash.
  • Financing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Investing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Operating reconciliation adjustments are not all independent cash receipts.
  • Net income enters operating cash directly in the reconciliation. The adjustment junction contributes the remaining $3.88B after reconciling the other positive and negative adjustments. These connections depict an accounting reconciliation, not traced cash receipts.
  • Each activity has one net cash bar connected to the shared cash pool. Positive activity totals enter the pool; negative activity totals leave the pool to fund that activity's net payments. The central pool does not assign a particular funding source to a particular payment.
  • The intermediate calculation bars include both sides of the displayed activity breakdowns; they are not additional cash flows.
  • Operating cash flow minus cash purchases of property, plant and equipment equals free cash flow: 5,447,000,000 US dollars minus 249,000,000 US dollars equals 5,198,000,000 US dollars.
AbbVie Inc. (ABBV) FY2024 Q3 Statement of Cash Flows Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!